Literature DB >> 29143217

Fluid biomarker agreement and interrelation in dementia due to Alzheimer's disease.

Panagiotis Alexopoulos1,2, Jennifer Roesler3, Lukas Werle3,4, Nathalie Thierjung3, Iliana Lentzari5, Marion Ortner3, Timo Grimmer3, Nikolaos Laskaris6, Antonios Politis7,8, Philippos Gourzis5, Alexander Kurz3, Robert Perneczky9,10,11,12.   

Abstract

The cerebrospinal fluid (CSF) levels of β-amyloid 42, total tau, and phosphorylated tau 181 are supposed to be all continuously abnormal in dementia due to Alzheimer's disease (AD), being the most advanced disease stage. The aim of the present study, which included a monocentric and a multicentric sample (N = 119 and 178, respectively), was to investigate the degree of CSF biomarker agreement and interrelation in AD dementia. Based on previously published cut-off values, biomarker values were categorized as positive or negative for AD (dichotomization strategy) and as either positive, negative, or borderline (trichotomization strategy). The statistical analyses relied on distance correlation analysis and kappa (k) statistics. Poor agreement (k < 0.4) and low interrelations between the studied biomarkers were detected in all cases with the exception of the interrelation between the markers total tau and phosphorylated tau 181, especially in the monocentric sample. Interestingly, lower interrelation and agreement degrees were observed in carriers of the Apolipoprotein E ε4 allele compared to non-carriers. The clinical phenotype currently referred to as "AD dementia" is characterized by an inhomogeneous CSF biomarker profile, possibly mirroring the complex genesis of AD-typical dementia symptoms and pointing to the necessity of shedding more light on the hypothesis of biomarker stability over time in symptomatic AD.

Entities:  

Keywords:  Phosphorylated tau 181; Total tau; β-Amyloid 1-42

Mesh:

Substances:

Year:  2017        PMID: 29143217     DOI: 10.1007/s00702-017-1810-z

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  50 in total

1.  Stage-dependent agreement between cerebrospinal fluid proteins and FDG-PET findings in Alzheimer's disease.

Authors:  Igor Yakushev; Matthias J Muller; Hans-Georg Buchholz; Ulrike Lang; Heidi Rossmann; Harald Hampel; Mathias Schreckenberger; Andreas Fellgiebel
Journal:  Curr Alzheimer Res       Date:  2012-02       Impact factor: 3.498

2.  The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey.

Authors:  Martina Bocchetta; Samantha Galluzzi; Patrick Gavin Kehoe; Eduardo Aguera; Roberto Bernabei; Roger Bullock; Mathieu Ceccaldi; Jean-François Dartigues; Alexandre de Mendonça; Mira Didic; Maria Eriksdotter; Olivier Félician; Lutz Frölich; Hermann-Josef Gertz; Merja Hallikainen; Steen G Hasselbalch; Lucrezia Hausner; Isabell Heuser; Frank Jessen; Roy W Jones; Alexander Kurz; Brian Lawlor; Alberto Lleo; Pablo Martinez-Lage; Patrizia Mecocci; Shima Mehrabian; Andreas Monsch; Flavio Nobili; Agneta Nordberg; Marcel Olde Rikkert; Jean-Marc Orgogozo; Florence Pasquier; Oliver Peters; Eric Salmon; Carmen Sánchez-Castellano; Isabel Santana; Marie Sarazin; Latchezar Traykov; Magda Tsolaki; Pieter Jelle Visser; Åsa K Wallin; Gordon Wilcock; David Wilkinson; Henrike Wolf; Görsev Yener; Dina Zekry; Giovanni B Frisoni
Journal:  Alzheimers Dement       Date:  2014-08-20       Impact factor: 21.566

3.  Apolipoprotein E genotyping by one-stage PCR.

Authors:  P R Wenham; W H Price; G Blandell
Journal:  Lancet       Date:  1991-05-11       Impact factor: 79.321

4.  Apolipoprotein E4 Impairs Neuronal Insulin Signaling by Trapping Insulin Receptor in the Endosomes.

Authors:  Na Zhao; Chia-Chen Liu; Alexandra J Van Ingelgom; Yuka A Martens; Cynthia Linares; Joshua A Knight; Meghan M Painter; Patrick M Sullivan; Guojun Bu
Journal:  Neuron       Date:  2017-09-27       Impact factor: 17.173

5.  Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.

Authors:  Tobias Skillbäck; Bahman Y Farahmand; Christoffer Rosén; Niklas Mattsson; Katarina Nägga; Lena Kilander; Dorota Religa; Anders Wimo; Bengt Winblad; Jonathan M Schott; Kaj Blennow; Maria Eriksdotter; Henrik Zetterberg
Journal:  Brain       Date:  2015-06-30       Impact factor: 13.501

6.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

7.  Mapping CSF biomarker profiles onto NIA-AA guidelines for Alzheimer's disease.

Authors:  Panagiotis Alexopoulos; Jennifer Roesler; Nathalie Thierjung; Lukas Werle; Dorothea Buck; Igor Yakushev; Lena Gleixner; Simone Kagerbauer; Marion Ortner; Timo Grimmer; Hubert Kübler; Jan Martin; Nikolaos Laskaris; Alexander Kurz; Robert Perneczky
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-08-08       Impact factor: 5.270

8.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.

Authors:  Victor L Villemagne; Samantha Burnham; Pierrick Bourgeat; Belinda Brown; Kathryn A Ellis; Olivier Salvado; Cassandra Szoeke; S Lance Macaulay; Ralph Martins; Paul Maruff; David Ames; Christopher C Rowe; Colin L Masters
Journal:  Lancet Neurol       Date:  2013-03-08       Impact factor: 44.182

9.  Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay.

Authors:  M Vandermeeren; M Mercken; E Vanmechelen; J Six; A van de Voorde; J J Martin; P Cras
Journal:  J Neurochem       Date:  1993-11       Impact factor: 5.372

10.  A diagnostic scale for Alzheimer's disease based on cerebrospinal fluid biomarker profiles.

Authors:  Sylvain Lehmann; Julien Dumurgier; Susanna Schraen; David Wallon; Frédéric Blanc; Eloi Magnin; Stéphanie Bombois; Olivier Bousiges; Dominique Campion; Benjamin Cretin; Constance Delaby; Didier Hannequin; Barbara Jung; Jacques Hugon; Jean-Louis Laplanche; Carole Miguet-Alfonsi; Katell Peoc'h; Nathalie Philippi; Muriel Quillard-Muraine; Bernard Sablonnière; Jacques Touchon; Olivier Vercruysse; Claire Paquet; Florence Pasquier; Audrey Gabelle
Journal:  Alzheimers Res Ther       Date:  2014-06-26       Impact factor: 6.982

View more
  1 in total

1.  Beneficial association of angiotensin-converting enzyme inhibitors and statins on the occurrence of possible Alzheimer's disease after traumatic brain injury.

Authors:  Mingfei Li; Joel Reisman; Benjamin Morris-Eppolito; Shirley X Qian; Lewis E Kazis; Benjamin Wolozin; Lee E Goldstein; Weiming Xia
Journal:  Alzheimers Res Ther       Date:  2020-03-27       Impact factor: 6.982

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.